Results 111 to 120 of about 9,306,982 (363)

Alpha Methyldopahydrazine as an Adjunct to Levodopa Therapy in Parkinson’s Disease [PDF]

, 1975
D. W. Paty, N. Jaatoul, Ann Kertesz, W. McInnis   +3 more
openalex   +1 more source

Additional file 1 of Altered gut microbiota and inflammatory cytokine responses in patients with Parkinsonâ s disease

, 2019
: Supplementary methods. (DOCX 21Â kb)
Chin-Hsien Lin, Chieh-Chang Chen, Chiang, Han-Lin, Jyh-Ming Liou, Chih-Min Chang, Tzu-Pin Lu, Chuang, Eric, Tai, Yi-Cheng, Chieh Cheng, Han-Yi Lin, Ming-Shiang Wu   +10 more
openaire   +1 more source

Nanomaterial‐Enhanced Biosensing: Mechanisms and Emerging Applications

Advanced Healthcare Materials, EarlyView.
Nanomaterial integration transforms biosensor capabilities through enhanced signal transduction, sensitivity, and selectivity. This review analyzes how nanoscale materials—from nanoparticles to nanosheets—leverage unique physicochemical properties to revolutionize electrochemical, optical, and electrical biosensing.
Younghak Cho, Yunyoung Choi, Yerim Jang, Hyejeong Seong   +3 more
wiley   +1 more source

Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease

Frontiers in Molecular Neuroscience, 2019
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease.
Carroll Rutherford Fields, Nora Bengoa-Vergniory, Richard Wade-Martins   +2 more
doaj   +1 more source

Bromocriptine in Parkinson’s Disease: Results Obtained With High and Low Dose Therapy [PDF]

, 1984
J. David Grimes
openalex   +1 more source

Aging on Chip: Harnessing the Potential of Microfluidic Technologies in Aging and Rejuvenation Research

Advanced Healthcare Materials, EarlyView.
This review highlights recent advances in microfluidic technologies for modeling human aging and age‐related diseases. It explores how organ‐on‐chip platforms improve physiological relevance, enable rejuvenation strategies, facilitate drug screening, detect senescent cells, and identify biomarkers.
Limor Zwi‐Dantsis, Vignesh Jayarajan, George M. Church, Roger D. Kamm, João Pedro de Magalhães, Emad Moeendarbary   +5 more
wiley   +1 more source

New Data on the Genetics of Parkinson’s Disease [PDF]

, 1982
André Barbeau, Emmanuelle Pourcher
openalex   +1 more source

Parkinson’s Disease: Time, Place, Person and Survival

Siriraj Medical Journal, 2009
-
Weerasak Muangpaisan, David Seidel, Hiroyuki Hori, Aju Mathews   +3 more
openaire   +1 more source

Additional file 1: of Parkinsonâ s disease in China: a forty-year growing track of bedside work

, 2019
Table S1. Epidemiology of PD in China. Table S2. Status of Clinical Trials. Data S3. Meta analysis of genetic variants for Parkinsonâ s disease in Chinese population. (DOCX 38298 kb)
Li, Gen, Ma, Jianfang, Cui, Shishuang, He, Yixi, Xiao, Qin, Liu, Jun, Chen, Shengdi   +6 more
openaire   +1 more source

Immunomodulation With Local, Sustained Delivery of Pituitary Adenylate Cyclase Activating Polypeptide Results in Improved Functional Recovery in Stroke‐Injured Mice

Advanced Healthcare Materials, EarlyView.
The tissue and functional benefits are demonstrated with local, sustained delivery of an anti‐inflammatory peptide, pituitary adenylate cyclase‐activating polypeptide (PACAP), for stroke treatment in a mouse model. Prolonged PACAP treatment modulated astrocyte and microglia toward pro‐reparative phenotypes, enhanced neuroprotection and preservation of ...
Eric Ho, David Xinzheyang Li, Hong Cui, Dania Akbar, Ricky Siu, Cindi M. Morshead, David Chatenet, Molly S. Shoichet   +7 more
wiley   +1 more source